Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HRK
REST API REST API
Homo sapiens
HRK is differentially expressed in 240 experiments: 86 organism parts: dorsal root ganglion, thymus, ... (84 more);, 152 disease states: normal, control, ... (150 more);, 74 cell types 289 cell lines 20 compound treatments and 80 other conditions.
Synonyms DP5
Orthologs Hrk (Mus musculus)   Hrk (Rattus norvegicus)   HRK (Canis familiaris)   HRK (Bos taurus)   (Compare orthologs)
Gene Ontology Term protein binding, apoptosis, induction of apoptosis, regulation of apoptosis, negative regulation of survival gene product expression, cellular response to potassium ion starvation, positive regulation of release of cytochrome c from mitochondria, positive regulation of neuron apoptosis, positive regulation of protein homooligomerization
InterPro Term Apoptosis_activator_harakiri
UniProt Accession O00198
Search EB-eye ENSG00000135116
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (34 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HuT78
1
E-MTAB-37
D283Med
1
E-MTAB-37
HMEC S1
1
E-MEXP-1006
283 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-GEOD-20677, ... (42 experiments)

Factor Value U/D Experiments
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-13987, E-GEOD-26672
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
native fetal RPE
1
E-GEOD-18811
platelet
1
E-GEOD-2006
memory B cell
1
E-MEXP-2360
68 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1577, E-GEOD-9692, ... (47 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-20295, E-GEOD-16363
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
engineered non-invasive esophageal squamous cell carcinoma
1
E-GEOD-21293
benign prostatic hyperplasia
1
E-MEXP-2034
idiopathic dilated cardiomyopathy
1
E-GEOD-1145
ovarian carcinoma
1
E-MTAB-37
146 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-15205, E-GEOD-5824, E-GEOD-15811, E-GEOD-5099, ... (14 experiments)

Factor Value U/D Experiments
none
4
E-GEOD-412, E-GEOD-5824, E-GEOD-1615, E-GEOD-2803
BCR/FGFR1
1
1
E-GEOD-15811
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
keratinocyte growth factor
1
E-GEOD-7216
NaOH
1
1
E-MEXP-2590
4-hydroxytamoxifen
2
1
E-MEXP-2241
14 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
37
2
1
E-GEOD-3494


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-GEOD-20505

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561, E-GEOD-980, E-GEOD-360 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-7179

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

No of metastases
studied in E-GEOD-22541

No of pulmonary metastases
studied in E-GEOD-22541

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Processing time: 0.252 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM